United Therapeutics Gains on Development of New Inhaler, 4Q Net Income Beat

Dow Jones

02/26

By Amira McKee

Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year.

The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year.

Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers.

United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027.

Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note.

United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compared with $301.3 million, or $6.19 a share, a year earlier.

The results beat Wall Street's forecast for a net income of $318.7 million, according to FactSet.

Revenue grew 7.4%, to $790.2 million, missing the $811.4 million that analysts polled by FactSet had anticipated.

Revenue from Tyvaso, a treatment for pulmonary arterial hypertension that makes up most of the company's top-line, grew 12%, to $464.3 million.

The breathable-powder form of the drug brought $63.5 million more in revenue this quarter, largely due to a higher number of patients, the company said.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

February 25, 2026 13:25 ET (18:25 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2614030678"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614030678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614030678?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 02:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614030678","market":"hk","top_or_hot":-1,"title":"United Therapeutics Gains on Development of New Inhaler, 4Q Net Income Beat","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. \n</p>\n<p>\n  The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year. \n</p>\n<p>\n  Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers. \n</p>\n<p>\n  United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027. \n</p>\n<p>\n  Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note. \n</p>\n<p>\n  United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compared with $301.3 million, or $6.19 a share, a year earlier. \n</p>\n<p>\n  The results beat Wall Street's forecast for a net income of $318.7 million, according to FactSet. \n</p>\n<p>\n  Revenue grew 7.4%, to $790.2 million, missing the $811.4 million that analysts polled by FactSet had anticipated. \n</p>\n<p>\n  Revenue from Tyvaso, a treatment for pulmonary arterial hypertension that makes up most of the company's top-line, grew 12%, to $464.3 million. \n</p>\n<p>\n  The breathable-powder form of the drug brought $63.5 million more in revenue this quarter, largely due to a higher number of patients, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 13:25 ET (18:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics Gains on Development of New Inhaler, 4Q Net Income Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics Gains on Development of New Inhaler, 4Q Net Income Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-26 02:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. \n</p>\n<p>\n  The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year. \n</p>\n<p>\n  Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers. \n</p>\n<p>\n  United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027. \n</p>\n<p>\n  Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note. \n</p>\n<p>\n  United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compared with $301.3 million, or $6.19 a share, a year earlier. \n</p>\n<p>\n  The results beat Wall Street's forecast for a net income of $318.7 million, according to FactSet. \n</p>\n<p>\n  Revenue grew 7.4%, to $790.2 million, missing the $811.4 million that analysts polled by FactSet had anticipated. \n</p>\n<p>\n  Revenue from Tyvaso, a treatment for pulmonary arterial hypertension that makes up most of the company's top-line, grew 12%, to $464.3 million. \n</p>\n<p>\n  The breathable-powder form of the drug brought $63.5 million more in revenue this quarter, largely due to a higher number of patients, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2026 13:25 ET (18:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614030678","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614030678","pubTimestamp":1772043900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year.The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year.Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers.United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027.Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note.United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compare","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"United Therapeutics因开发新型吸入器而获利，第四季度净利润超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1.5},"content_text":"By Amira McKee \n\n\n \n\n\n  Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. \n\n\n  The stock rose 9%, to $515.94, midday Wednesday and have gained 44% in the past year. \n\n\n  Chief Executive Martine Rothblatt said Wednesday that the biotechnology company was developing a soft-mist inhaler designed to alleviate the side effect of coughing from traditional dry-powder inhalers. \n\n\n  United Therapeutics intends to file to have the formulation approved to treat pulmonary arterial hypertension and interstitial lung disease and plans to commercially launch the product in 2027. \n\n\n  Though the Silver Spring, Md., company offered few insights into the program, the new formulation and the short release timeline could give United Therapeutics an edge against its competition in the dry-powder-inhalation space, analysts at Cantor said in a research note. \n\n\n  United Therapeutics reported a fourth-quarter net income of $364.3 million, or $7.70 a share, compared with $301.3 million, or $6.19 a share, a year earlier. \n\n\n  The results beat Wall Street's forecast for a net income of $318.7 million, according to FactSet. \n\n\n  Revenue grew 7.4%, to $790.2 million, missing the $811.4 million that analysts polled by FactSet had anticipated. \n\n\n  Revenue from Tyvaso, a treatment for pulmonary arterial hypertension that makes up most of the company's top-line, grew 12%, to $464.3 million. \n\n\n  The breathable-powder form of the drug brought $63.5 million more in revenue this quarter, largely due to a higher number of patients, the company said. \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 13:25 ET (18:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}